Marinus Pharmaceuticals’ (MRNS) Buy Rating Reaffirmed at Truist Financial

Truist Financial reiterated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Tuesday morning, Benzinga reports. Truist Financial currently has a $10.00 target price on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Robert W. Baird reiterated a neutral rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. Oppenheimer reaffirmed a market perform rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday. StockNews.com cut Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, March 6th. Finally, Royal Bank of Canada reaffirmed a sector perform rating and issued a $3.00 price target (down from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $13.79.

Marinus Pharmaceuticals Trading Down 3.8 %

Shares of MRNS opened at $1.40 on Tuesday. The business has a 50-day moving average of $1.81 and a 200 day moving average of $6.82. Marinus Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.26. The firm has a market cap of $76.63 million, a P/E ratio of -0.53 and a beta of 1.11. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.93 and a current ratio of 3.07.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, hitting the consensus estimate of ($0.68). The company had revenue of $7.68 million during the quarter, compared to analyst estimates of $8.61 million. Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Eventide Asset Management LLC increased its position in Marinus Pharmaceuticals by 42.8% during the third quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock valued at $36,466,000 after acquiring an additional 1,356,800 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after buying an additional 990,607 shares in the last quarter. abrdn plc purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $6,006,000. Superstring Capital Management LP purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $5,027,000. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of Marinus Pharmaceuticals by 6.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after purchasing an additional 173,226 shares in the last quarter. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.